Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Jun 10, 2024
- Pharmaceuticals
- R&D
Roche Announces New Five-Year Data of Evrysdi for Type I SMA
TOKYO, June 10, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on June 7, regarding five-year data from the FIREFISH study of Evrysdi® (generic name: risdiplam) in type I SMA.
Please refer to the link below for details of the press release:
Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk
